PT  - JOURNAL ARTICLE
AU  - McKeigue, Paul M
AU  - McGurnaghan, Stuart
AU  - Blackbourn, Luke
AU  - Bath, Louise E
AU  - McAllister, David A
AU  - Caparrotta, Thomas M
AU  - Wild, Sarah H
AU  - Wood, Simon N
AU  - Stockton, Diane
AU  - Colhoun, Helen M
TI  - Relation of incident Type 1 diabetes to recent COVID-19 infection: cohort study using e-health record linkage in Scotland
AID  - 10.1101/2022.02.11.22270785
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.11.22270785
4099  - http://medrxiv.org/content/early/2022/02/11/2022.02.11.22270785.short
4100  - http://medrxiv.org/content/early/2022/02/11/2022.02.11.22270785.full
AB  - Background Studies using claims databases have reported that SARS-CoV-2 infection >30 days earlier increased the incidence of type 1 diabetes (T1DM). Using exact dates of type 1 diabetes diagnosis from the national register in Scotland linked to virology laboratory data we sought to replicate this finding.Methods A cohort of 1849411 individuals aged <35 years without diabetes, including all those in Scotland who subsequently tested positive for SARS-CoV-2, was followed from 1 March 2020 to 22 November 2021. Incident T1DM was identified by linkage to the national registry. Cox regression was used to test the association of time-updated infection with incident T1DM. Trends in incidence of T1DM in the total population from 2015-2021 were estimated in a generalized additive model.Findings There were 365080 in the cohort with at least one detected SARS-CoV-2 infection during follow-up and 1074 who developed T1DM. The rate ratio for incident T1DM associated with first positive test for SARS-CoV-2 (with no previous infection as reference category) was 0.88 (95% CI 0.63 to 1.23) for infection more than 30 days earlier and 2.62 (95% CI 1.81 to 3.79) for infection in the previous 30 days. However negative and positive SARS-CoV-2 tests were more frequent in the days surrounding T1DM presentation. In those aged 0-14 years incidence of T1DM during 2020-2021 was 20% higher than the 7-year average.Interpretation T1DM incidence in children increased during the pandemic. However the cohort analysis does not support a causal effect of SARS-CoV-2 infection itself on T1DM incidence.Funding NoneCompeting Interest StatementHC Advisory Board: Novo-Nordisk, Bayer, Eli Lilly, Regeneron, Astra Zeneca, Meeting attendance support: Novo Nordisk, Eli Lilly, Regeneron, Stock: Bayer Roche Grant Research Funding Diabetes UK,Juvenile Diabetes Research Foundation, AXA Research Fund. PMCK Stock: Bayer Roche. SW Meeting attendance support: Novo Nordisk. TC Grant Supprt Diabetes UK, Leadership: Edinburgh High Blood Pressure Fund TrusteeClinical Protocols https://osf.io/rfzk7/ Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for use of the diabetes data was provided by the Public Benefit and Privacy Panel (https://www.informationgovernance.scot.nhs.uk/pbpphsc/) (ref. 1617-0147) and the Scotland A Multicentre Research Ethics Committee (ref 21/WS/0047). The REACT-SCOT study was performed within Public Health Scotland as part of its statutory duty to monitor and investigate public health problems and pandemic response. Under the [UK Policy Framework for Health and Social Care Research](https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/) set out by the NHS Health Research Authority, this does not fall within the definition of research and ethical review was therefore not required. This has been confirmed in writing by the NHS West of Scotland Research Ethics Service. Individual consent is not required for Public Health Scotland staff to process personal data to perform specific tasks in the public interest that fall within its statutory role. The statutory basis for this is set out in Public Health Scotland's [privacy notice](https://www.publichealthscotland.scot/our-privacy-notice/personal-data-processing/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe component datasets used here are available to researchers via application to the Public Benefits and Privacy Panel for Health and Social Care https://www.informationgovernance.scot.nhs.uk/pbpphsc/ https://www.informationgovernance.scot.nhs.uk/pbpphsc/